Celldex Therapeutics, Inc. Earnings

Celldex Therapeutics, Inc.’s revenue fell -70.78% since last year same period to $0.73Mn in the Q2 2025. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated 5.04% jump in its revenue since last 3-months.

Celldex Therapeutics, Inc.’s net profit fell -57.92% since last year same period to $-56.6Mn in the Q2 2025. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -5.21% fall in its net profits since last 3-months.

Celldex Therapeutics, Inc.’s net profit margin fell -440.37% since last year same period to -7753.42% in the Q2 2025. On a quarterly growth basis, Celldex Therapeutics, Inc. has generated -0.17% fall in its net profit margins since last 3-months.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.9 - a -4.48% fall from last quarter’s estimates.

Celldex Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.9.

Celldex Therapeutics, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Celldex Therapeutics, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.